Genomic Health Sets Sights on Expanding Oncotype DX for Later-Stage Colorectal Cancer, Other Areas

Oncotype DX for colorectal cancer recurrence in stage II patients may have just launched, but Genomic Health is already working to expand the test's indication into later stages of the disease. Also, the company is not giving up on the predictive indication of the test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.